Root of an Indian climbing plant with a narrow but real controlled human evidence base. Strongest finding is symptom relief at the end of menstruation — heat surges, night sweats, broken sleep, irritability, dryness. Milk supply after birth and muscle function in older women look promising, not firm. Most menopause trials were company-funded; a powder was recalled for lead. (Full Review)

Protocol

Standard extract dose

300 mg once daily

Standardized root extract; most-replicated protocol, used in the perimenopause, lactation and sexual-function trials. 100–500 mg daily spans the full trial range.

High-dose musculoskeletal protocol

1,000 mg daily

Aqueous root extract, taken throughout an eight-week progressive resistance training program.

Best time of day

Morning, with food

No study of time-of-day dosing exists; trials dosed once daily without a specified time. Evening dosing has no demonstrated sleep benefit or penalty.

Time to effect

Menopausal symptoms

4–8 weeks

Symptom scores separate from placebo at four weeks and widen by eight.

Lactation

72 hours

Postpartum trials dosed 300 mg twice daily over this window.

Muscle and bone

6–24 weeks

Only alongside progressive resistance training; bone findings are contradicted.

Benefits

High: Relief of perimenopausal and menopausal symptoms

Medium: Increased breast milk output postpartum; improved muscle contractile function and training capacity; reduced perceived stress and mood disturbance; reduced bone resorption

Low: Improved female sexual function; improved ovarian morphology in polycystic ovary syndrome; accelerated gastric emptying; lower inflammatory and oxidative stress markers

Speculative: Immune modulation; cognitive protection and neuroprotection; glucose and lipid regulation; antiproliferative activity in cancer cell lines

Contraindications

Personal history of estrogen-receptor-positive breast, endometrial or ovarian cancer, or current use of tamoxifen or an aromatase inhibitor

Documented asparagus allergy (contact dermatitis, oral allergy syndrome, asparagus-triggered asthma)

Pregnancy

Advanced chronic kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m²)

Children and adolescents under 18

Key Interactions

Antidiabetic drugs (metformin, glipizide, insulin)

Lithium

Thyroid hormone replacement (levothyroxine)

Delayed-release and narrow-therapeutic-index oral drugs (warfarin, digoxin)

Over-the-counter analgesics and acid reducers (ibuprofen, aspirin, omeprazole)

Diuretics (furosemide, hydrochlorothiazide) and antihypertensives

Estrogen therapy, oral contraceptives and selective estrogen receptor modulators (raloxifene)

Other phytoestrogen supplements (soy isoflavones, red clover, black cohosh)

Ashwagandha

Other supplements with additive effects (fenugreek, berberine, chromium)

Risk & Side Effects

High: Heavy metal contamination of root powders

Medium: Mild gastrointestinal disturbance

Low: Unpredictable shifts in reproductive hormones; allergic reactions in asparagus-sensitized people; altered absorption of co-administered medications

Speculative: Hypoglycemia alongside glucose-lowering therapy; diuresis and lithium accumulation; stimulation of hormone-sensitive tumors

Monitoring

Marker	Target	Why
Whole blood lead	< 1 µg/dL	Detects contamination carried by the product
Estradiol	No target on shatavari; track own baseline	Trials disagree on direction of change
Follicle-stimulating hormone (FSH)	No target on shatavari; track own baseline	One trial found it rose, another that it fell
Alanine aminotransferase (ALT)	10–26 U/L	Confirms the absence of liver injury seen with some Ayurvedic products
Estimated glomerular filtration rate (eGFR)	> 90 mL/min/1.73 m²	Governs clearance of any absorbed heavy metal
High-sensitivity C-reactive protein (hs-CRP)	< 1.0 mg/L	The inflammatory endpoint that moved in the largest trial
Glycated hemoglobin (HbA1c)	4.8–5.4%	Screens the theoretical glucose-lowering risk
Thyroid-stimulating hormone (TSH) and free triiodothyronine (free T3)	TSH 0.5–2.5 mIU/L; free T3 upper half of range	One trial recorded a rise in triiodothyronine on shatavari
Prolactin	No target; track own baseline	The proposed mechanism for the lactation effect

Cadence: Baseline before starting; symptom score at 4 and 8 weeks; hormones, liver and kidney panels at 12 weeks, then every 6–12 months; blood lead annually where use is continuous.

Qualitative Assessment

Hot flash and night sweat frequency, counted daily for a representative week
Sleep continuity — number of night wakings, not just total hours
Perceived stress and irritability, ideally on the same validated scale used at baseline
Grip strength and perceived training capacity, if resistance training is part of the protocol
Vaginal dryness and sexual comfort
Digestive tolerance — loose stools or nausea in the first two weeks

Shatavari for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment